Analysts' Top Healthcare Picks: Radiopharm Theranostics Limited Sponsored ADR (RADX), Mediwound (MDWD)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Radiopharm Theranostics Limited Sponsored ADR (RADX – Research Report) and Mediwound (MDWD – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Radiopharm Theranostics Limited Sponsored ADR (RADX)
JonesTrading analyst Justin Walsh reiterated a Buy rating on Radiopharm Theranostics Limited Sponsored ADR on May 22 and set a price target of $30.00. The company's shares closed last Friday at $4.81, close to its 52-week low of $3.55.
According to TipRanks.com, Walsh is ranked 0 out of 5 stars with an average return of -5.4% and a 28.2% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Actinium Pharmaceuticals, and Perspective Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Radiopharm Theranostics Limited Sponsored ADR.
Mediwound (MDWD)
In a report issued on May 22, Michael Okunewitch from Maxim Group maintained a Buy rating on Mediwound, with a price target of $30.00. The company's shares closed last Friday at $20.37.
According to TipRanks.com, Okunewitch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -19.5% and a 34.3% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Acrivon Therapeutics, Inc., and Rani Therapeutics Holdings.
Mediwound has an analyst consensus of Strong Buy, with a price target consensus of $28.67, a 43.5% upside from current levels. In a report issued on May 19, Craig-Hallum also initiated coverage with a Buy rating on the stock.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Analysts Are Neutral on Top Consumer Cyclical Stocks: Ulta Beauty (ULTA), Costco (COST)
Analysts fell to the sidelines weighing in on Ulta Beauty (ULTA – Research Report) and Costco (COST – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Ulta Beauty (ULTA) Barclays analyst Adrienne Yih maintained a Hold rating on Ulta Beauty on May 30 and set a price target of $485.00. The company's shares closed last Friday at $471.46. According to Yih is a 4-star analyst with an average return of 6.3% and a 49.0% success rate. Yih covers the NA sector, focusing on stocks such as National Vision Holdings, Dick's Sporting Goods, and Canada Goose Holdings. Ulta Beauty has an analyst consensus of Moderate Buy, with a price target consensus of $463.17, representing a -1.1% downside. In a report issued on May 15, Piper Sandler also maintained a Hold rating on the stock with a $386.00 price target. Costco (COST) Barclays analyst Seth Sigman maintained a Hold rating on Costco on May 30 and set a price target of $1000.00. The company's shares closed last Friday at $1040.18, close to its 52-week high of $1078.23. According to Sigman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.3% and a 53.7% success rate. Sigman covers the NA sector, focusing on stocks such as Driven Brands Holdings, Floor & Decor Holdings, and Advance Auto Parts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Costco with a $1081.82 average price target, representing a 7.9% upside. In a report issued on May 29, Wells Fargo also maintained a Hold rating on the stock with a $1000.00 price target.
Business Insider
2 days ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on scPharmaceuticals (SCPH – Research Report), 10x Genomics (TXG – Research Report) and Kura Oncology (KURA – Research Report). Confident Investing Starts Here: scPharmaceuticals (SCPH) Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals on May 14 and set a price target of $11.00. The company's shares closed last Friday at $3.22. According to Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 28.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $15.60 average price target, implying a 432.4% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock. 10x Genomics (TXG) In a report issued on May 14, Puneet Souda from Leerink Partners maintained a Hold rating on 10x Genomics. The company's shares closed last Friday at $9.39, close to its 52-week low of $8.92. According to Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 29.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $12.56, a 36.2% upside from current levels. In a report issued on May 9, TD Cowen also maintained a Hold rating on the stock with a $11.00 price target. Kura Oncology (KURA) In a report issued on May 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology, with a price target of $23.00. The company's shares closed last Friday at $6.02. According to Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 28.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics. Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 279.2% upside from current levels. In a report issued on May 1, TD Cowen also maintained a Buy rating on the stock.
Business Insider
2 days ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardant Health (GH – Research Report), AnaptysBio (ANAB – Research Report) and Alignment Healthcare (ALHC – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Guardant Health (GH) In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health, with a price target of $60.00. The company's shares closed last Monday at $44.05. According to Westenberg is a 3-star analyst with an average return of 3.1% and a 44.4% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Elanco Animal Health, and Pacific Biosciences. Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $59.26, which is a 29.4% upside from current levels. In a report issued on April 22, Leerink Partners also maintained a Buy rating on the stock. AnaptysBio (ANAB) In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on AnaptysBio, with a price target of $57.00. The company's shares closed last Monday at $20.73. According to Rahimi is a 1-star analyst with an average return of -1.0% and a 34.8% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio with a $45.57 average price target, which is a 120.2% upside from current levels. In a report issued on April 22, Wells Fargo also maintained a Buy rating on the stock with a $51.00 price target. Alignment Healthcare (ALHC) In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Alignment Healthcare, with a price target of $21.00. The company's shares closed last Monday at $15.48. According to Tassan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.8% and a 39.2% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Privia Health Group, Health Catalyst, and Evolent Health. Currently, the analyst consensus on Alignment Healthcare is a Moderate Buy with an average price target of $18.35, implying a 18.6% upside from current levels. In a report issued on May 2, TD Cowen also maintained a Buy rating on the stock with a $17.00 price target.
